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I n t r o d u c t I o n
Acute myocardial infarction is a potentially life-threatening disease that even in 
the current device-oriented era remains a challenge for the interventional cardiolo-
gist. The underlying pathological mechanism has been shown to be atherosclerotic 
plaque rupture or erosion with subsequent thrombus formation, which leads to coro-
nary artery occlusion and myocardial necrosis.1 In order to restore blood flow in the 
artery and prevent the detrimental effect of myocardial muscle loss, two strategic 
approaches have been shown to be mandatory. First of all it is pivotal to open the 
occluded artery and secondly it is imperative to prevent further fibrin deposition 
and platelet activation and aggregation. The latter is mainly achieved by giving oral 
antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor and administering an 
intravenous antithrombotic agent, such as heparin or bivalirudin.2 However, thrombus 
removal from the infarct related artery and reperfusion of the damaged myocardium 
has been proven to be a more complex issue. This is due to the fact that, even though 
the hypothesis of thrombotic material extraction which could result in better clinical 
outcome seems appealing and logical, the available studies have shown surprisingly 
conflicting results.3-5 Several mechanisms have been proposed to explain reperfusion 
failure during primary percutaneous coronary interventions (pPCI), despite the use of 
dedicated devices that remove thrombotic debris, leading to microvascular obstruction 
and myocardial injury.6-12
t h r o m b e c t o m y  d e v I c e s
Currently, there are four different types of devices that are designed to prevent 
distal embolization of atherothrombotic particles, distal occlusion/aspiration systems, 
filters, proximal occlusion/aspiration devices, and thrombectomy catheters.13-15 Thus 
far, there has been an abundance of evidence suggesting that during pPCI, the utiliza-
tion of filters and occlusion devices prior to stent implantation compared with stent 
implantation alone, does not offer any benefit regarding the extent of myocardium 
salvaged and the long term clinical outcome.16-20 On the other hand, devices that re-
move thrombotic material have shown promising results, with the more recent TAPAS 
(Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial 
infarction Study) trial exhibiting reduction of mortality in the thrombus aspiration 
population compared with the stent alone patients.3
To date various thrombectomy devices have been developed, that facilitate manual 
or mechanical removal of intracoronary thrombus. Mechanical thrombectomy devices, 
myocArdIAL InFArctIon & IschemIA therAPy uPdAte
First Department of Cardiology, 
Hippokration Hospital, Athens 
University Medical School, 
Athens, Greece






MACE = major cardiovascular events
PCI = primary percutaneous coronary 
intervention
pPCI = primary percutaneous coronary 
intervention
STEMI = ST elevation myocardial 
infarction
2HOSPITAL CHRONICLES 2014, VOLUME 9, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2014»
such as the X-Sizer and AngioJet devices, can remove large 
thrombi and effectively reduce the thrombotic burden, but 
are considered to be technically demanding to handle, time 
consuming to prepare, bulky and relatively expensive. Further-
more, the AIMI (AngioJet in Acute Myocardial Infarction) 
trial failed to show infarct size reduction or survival benefit 
in patients treated with rheolytic thrombectomy.21 These un-
favorable results, which came from a poorly designed trial, 
limited the use of mechanical thrombectomy in the subsequent 
years. The recently published JETSTENT (AngioJET Rheo-
lytic Thrombectomy Before Direct Infarct Artery STENTing 
with Direct Stenting Alone in Patients with Acute Myocardial 
Infarction) trial,22 which included 501 patients, showed a strong 
clinical benefit of rheolytic thrombectomy in the setting of 
pPCI for acute myocardial infarction and rekindled the inter-
est in rheolytic thrombectomy especially in the presence of 
large thrombus, where its use has been demonstrated to be 
a significant independent predictor of reduced risk of stent 
thrombosis and major adverse cardiac events (MACE).23,24
In contrast to mechanical thrombectomy that still needs 
to prove its efficacy in the high risk setting of pPCI and for 
this reason is not widely utilized, manual thrombectomy with 
aspiration catheters has been extensively employed, since the 
majority of trials exhibited favorable results.3,25-27 During the 
last few years, several catheters with different characteristics 
have been introduced in clinical practice. These catheters in-
clude the Export® AP Aspiration Catheter (Medtronic, MN, 
USA), the Fetch®2 Aspiration Catheter (MEDRAD, Inc.), the 
Diver™ CE (Invatec, Roncadelle, Italy), the Pronto™ (Vascu-
lar Solutions, MN, USA), the QuickCat™ (Spectranetics Inc., 
CO, USA), the Thrombuster II (Kaneka Corp. Japan), the 
Nipro’s TransVascular Aspiration Catheter (Osaka, Japan), 
the Eliminate aspiration catheter (Terumo Medical Supply, 
Japan) and the Hunter® (IHT Cordynamic, Barcelona, Spain). 
However, all the aforementioned aspiration catheters have 
similar design incorporating two lumens—one lumen for pas-
sage of the catheter over a coronary wire and a second lumen 
for manual aspiration of thrombus and atheromatous debris.
A s P I r A t I o n  t h r o m b e c t o m y
The first large scale randomized trial that compared aspira-
tion thrombectomy followed by stenting versus stenting alone 
in patients with acute myocardial infarction was the TAPAS 
trial.3,28,29 A total of 1,071 patients were randomly assigned 
to the thrombus-aspiration group or the conventional-PCI 
group before undergoing coronary angiography. The investi-
gators evaluated angiographic and electrocardiographic signs 
of myocardial reperfusion and assessed clinical outcome. 
Successful aspiration was confirmed in 72.9% of patients. A 
myocardial blush grade of 0 or 1 occurred in 17.1% of the 
patients in the thrombus-aspiration group and in 26.3% of 
those in the conventional-PCI group (P<0.001). Complete 
resolution of ST-segment elevation occurred in 56.6% and 
44.2% of patients, respectively (P<0.001).29 Moreover, at one 
year follow-up cardiac death was 3.6% in the thrombectomy 
group and 6.7% in the conventional PCI group (hazard ratio 
- HR 1.93; 95% confidence intervals-CI 1.11-3.37; p=0.020). 
Additionally, 1-year cardiac death or non-fatal reinfarction 
occurred in 5.6% of patients in the thrombus aspiration group 
and 9.9% of patients in the conventional PCI group (HR 1.81; 
95% CI 1.16-2.84; p=0.009).3
The favorable results observed in the TAPAS trial were 
confirmed by a meta-analysis that included 30 studies with 
6,415 patients.16 The investigators compared catheter thrombus 
aspiration, mechanical thrombectomy, and embolic protection 
with pPCI alone.16 The meta-analysis showed that manual 
thrombectomy improved myocardial perfusion and was asso-
ciated with lower mortality (2.7% for the catheter thrombus 
aspiration group vs. 4.4% for pPCI alone, P = 0.018).16 In 
another meta-analysis, De Luca and colleagues assessed nine 
randomized trials with 2,417 patients comparing PCI with aspi-
ration thrombectomy versus pPCI alone.30 This meta-analysis 
also found that patients treated with thrombectomy had less 
distal emboli (7.9 vs. 19.5%, P <0.0001), a higher frequency 
of TIMI 3 flow (87.1 vs. 81.2%, P <0.0001) and Myocardial 
Blush Grade 3 (52.1 vs. 31.7%, P <0.0001) post-PCI, and lower 
30-day mortality (1.7 vs. 3.1%, P = 0.04).30 The beneficial effect 
of thrombectomy on myocardial microcirculation may be due 
to the preservation of microvascular integrity.31 In a separate 
meta-analysis, Burzota and colleagues further investigated 
the impact of thrombectomy on long-term clinical outcome in 
a collaborative individual patient-data pooled analysis of 11 
randomized trials.32 Subgroup analysis was planned according 
to the type of thrombectomy device (manual or non-manual), 
diabetic status, IIb/IIIa-inhibitor therapy, ischemic time, 
infarct-related artery and pre-PCI TIMI flow. The study dem-
onstrated that manual thrombectomy significantly improved 
one-year survival in patients undergoing pPCI. Furthermore, 
after subgroup analysis, manual thrombectomy was associ-
ated with improved survival in patients treated with IIb/IIIa-
inhibitors.32 The results of the aforementioned study suggest 
that manual thrombectomy significantly improves the clinical 
outcome in patients with pPCI and its effect may be additional 
to that of IIb/IIIa-inhibitors.
A more recent prospective, non-randomized trial from 
Leiden sought to investigate whether there is an adjunctive 
effect of thrombus aspiration among patients with acute 
myocardial infarction and angiographic evidence of thrombus, 
receiving prehospital abciximab.27 ST-segment resolution was 
significantly higher in the thrombectomy-facilitated group, 
and multivariate analysis identified thrombectomy as an 
independent predictor of ST-segment resolution. Addition-
ally, distal embolization was higher in the conventional pPCI 
group among patients with higher thrombus grades and at 12 
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month clinical follow-up, thrombus aspiration was associated 
with reduced all-cause mortality (log-rank p = 0.032).27 In 
contrast, the INFUSE-AMI randomized trial demonstrated 
that, in patients with large anterior ST-segment elevation 
myocardial infarction (STEMI) undergoing primary PCI with 
bivalirudin anticoagulation, bolus intracoronary abciximab 
significantly reduced infarct size at 30 days but not manual 
aspiration thrombectomy.33 However, the investigators ob-
served that from randomization to 1 year, thrombus aspiration 
compared with no aspiration was associated with lower rates 
of new-onset severe heart failure (0.9% versus 4.5%; P=0.02) 
and of rehospitalization for heart failure (0.9% versus 5.4%; 
P=0.0008), but with non-significantly different rates of mortal-
ity.34 Therefore, the results of INFUSE-AMI further support 
the use of thrombus aspiration combined with intralesional 
abciximab in patients with anterior STEMI undergoing pPCI 
with bivalirudin anticoagulation.34
Subsequent to the previous favorable results, both the 
European Society of Cardiology (ESC) and the recently up-
dated 2013 ACCF/AHA STEMI guidelines endorsed the use 
of aspiration thrombectomy with pPCI in STEMI, with a Class 
IIa (Level of Evidence: B) recommendation.35,36 Even so, the 
use of aspiration thrombectomy during pPCI has remained 
controversial. This is perhaps due to the fact that, even though 
removal of some thrombus at the culprit lesion site may prevent 
distal embolization, improve epicardial coronary flow, and 
therefore reduce microvascular obstruction and no-reflow, the 
thrombectomy catheter itself may cause distal thrombus em-
bolization. Moreover, its use adds to procedural time. Hence, 
there are still concerns regarding its unrestricted application 
in all patients undergoing pPCI and it has been argued that 
the majority of evidence is based on small scale trials that did 
not have the power to determine survival benefit.37
The recently published TASTE trial (Thrombus Aspira-
tion before PCI in STEMI) was undertaken in order to shed 
more light in the role of manual thrombectomy.38 TASTE was 
a multicenter, prospective, randomized, controlled, clinical 
open-label trial based on the Swedish angiography and an-
gioplasty registry platform with blinded evaluation of end 
points.38 The investigators observed that death from any cause 
occurred in 2.8% of the patients in the thrombus-aspiration 
group, as compared with 3.0% in the pPCI alone group (HR 
0.94; 95% CI, 0.72 to 1.22; P=0.63). The rates of hospitaliza-
tion for recurrent myocardial infarction at 30 days were 0.5% 
and 0.9% in the two groups, respectively (HR 0.61; 95% 
CI, 0.34 to 1.07; P=0.09), and the rates of stent thrombosis 
were 0.2% and 0.5%, respectively (HR 0.47; 95% CI, 0.20 to 
1.02; P=0.06). The study did not show any significant differ-
ences between the groups with respect to the rate of stroke 
or neurologic complications.5 The results of TASTE do not 
support routine thrombus aspiration before pPCI in patients 
with STEMI and raise more questions regarding the optimal 
management of those patients.
Ongoing are two more trials that compare manual throm-
bus aspiration with pPCI alone, PATA STEMI and TOTAL. 
The PATA STEMI (The Randomized Physiologic Assessment 
of Thrombus Aspiration in Patients with Acute ST-Segment 
Elevation Myocardial Infarction Trial) study aims to determine 
whether manual thrombus aspiration increases myocardial 
perfusion assessed by index of microcirculatory resistance.39 
The multicenter, prospective, open, international, randomized 
TOTAL trial (ThrOmbecTomy with percutaneous coronary 
intervention versus PCI ALone) is designed to evaluate the 
efficacy of routine upfront manual aspiration thrombectomy 
and will recruit 10,700 patients.40
c o n c L u s I o n
Manual thrombectomy is easily applicable and several 
studies have confirmed its favorable effect on myocardial 
perfusion, especially when it is combined with adjunctive 
pharmacotherapy, such as the intracoronary administration of 
IIb/IIIa agents. However, there is no doubt that the TASTE 
trial will impact everyday clinical practice at least up to a point 
and until the newer randomized trials further clarify the role 
and the indications of manual thrombectomy in patients with 
STEMI submitted to pPCI.
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